09969.HK
InnoCare Pharma Limited
HKSE · Healthcare · Biotechnology · CN
HKD 15.37
+4.06%Year over year
Reported trailing growth
- Revenue
- +108.5%
- EBITDA
- +410.4%
- EBIT
- +200.9%
- EPS
- +479.6%
- Free cash flow
- +222.4%
- Operating cash flow
- +321.4%
Forward estimates
Based on analyst estimates
- Revenue
- -54.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +54.3%
- EBITDA
- +219.9%
- EBIT
- +183.8%
- Net income
- +242.0%
- EPS
- +238.5%
- Free cash flow
- +129.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026